Literature DB >> 14715820

A randomized controlled trial of orbital radiotherapy versus sham irradiation in patients with mild Graves' ophthalmopathy.

Mark F Prummel1, Caroline B Terwee, Martin N Gerding, Lelio Baldeschi, Maarten P Mourits, Leo Blank, Friedo W Dekker, Wilmar M Wiersinga.   

Abstract

Radiotherapy is often used in Graves' ophthalmopathy, but its efficacy has been doubted. We compared its efficacy with sham irradiation in mild ophthalmopathy. In a double-blind randomized trial, 44 patients received orbital irradiation, and 44 were sham-irradiated. The primary outcome was assessed using major and minor criteria. As secondary outcome, we used a disease-specific quality of life questionnaire (the GO-QoL) and compared cost-effectiveness and need for follow-up treatment. The primary outcome was successful in 23 of 44 (52%) irradiated patients vs. 12 of 44 (27%) sham-irradiated patients at 12 months after treatment (relative risk, 1.9; 95% confidence interval, 1.1-3.4; P = 0.02). Radiotherapy was effective in improving eye muscle motility and decreasing the severity of diplopia. However, quality of life improved similarly in both groups. In the radiotherapy group there was less need for follow-up treatment; 66% vs. 84% of the patients needed further treatment (P = 0.049). Retrobulbar irradiation did not prevent worsening of ophthalmopathy, which occurred in 14% of the irradiated and 16% of the sham-irradiated patients. Radiotherapy is an effective treatment in mild ophthalmopathy. However, the improvement upon irradiation may not be associated with an increase in quality of life or a reduction in treatment costs.

Entities:  

Mesh:

Year:  2004        PMID: 14715820     DOI: 10.1210/jc.2003-030809

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  44 in total

Review 1.  Recent developments in thyroid eye disease.

Authors:  Tom Cawood; Paul Moriarty; Donal O'Shea
Journal:  BMJ       Date:  2004-08-14

Review 2.  An update on medical management of Graves' ophthalmopathy.

Authors:  L Bartalena; C Marcocci; M L Tanda; E Piantanida; A Lai; M Marinò; A Pinchera
Journal:  J Endocrinol Invest       Date:  2005-05       Impact factor: 4.256

Review 3.  Graves orbitopathy: a perspective.

Authors:  Petros Perros; Gerasimos E Krassas
Journal:  Nat Rev Endocrinol       Date:  2009-06       Impact factor: 43.330

Review 4.  Insulin-like Growth Factor-I Receptor and Thyroid-Associated Ophthalmopathy.

Authors:  Terry J Smith; Joseph A M J L Janssen
Journal:  Endocr Rev       Date:  2019-02-01       Impact factor: 19.871

5.  Effect of radiotherapy on moderate and severe thyroid associated ophthalmopathy: a double blind and self-controlled study.

Authors:  Yujie Wu; Boding Tong; Yongheng Luo; Guiyuan Xie; Wei Xiong
Journal:  Int J Clin Exp Med       Date:  2015-02-15

6.  [Drug therapy and radiotherapy in Graves' orbitopathy].

Authors:  F Beisse; W A Lagrèze; M Schmucker
Journal:  Ophthalmologe       Date:  2011-05       Impact factor: 1.059

7.  Improvement of the MRI and clinical features of Asian Graves' ophthalmopathy by radiation therapy with steroids.

Authors:  Zichang Ma; Hiroshi Ozaki; Yojiro Ishikawa; Keiichi Jingu
Journal:  Jpn J Radiol       Date:  2019-06-14       Impact factor: 2.374

Review 8.  Orbital Decompression for Thyroid Eye Disease.

Authors:  Tara L Braun; Mohin A Bhadkamkar; Kevin T Jubbal; Adam C Weber; Douglas P Marx
Journal:  Semin Plast Surg       Date:  2017-02       Impact factor: 2.314

Review 9.  The effect of orbital radiation therapy on thyroid-associated orbitopathy complicated with dysthyroid optic neuropathy.

Authors:  Yang Wang; Huifang Zhou; Xianqun Fan
Journal:  Front Med       Date:  2017-05-13       Impact factor: 4.592

10.  Update on the medical treatment of Graves' ophthalmopathy.

Authors:  Gregory J Griepentrog; James A Garrity
Journal:  Int J Gen Med       Date:  2009-12-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.